Oncentra Oncology Software Solution – The Choice of Det Norske Radiumhospitalet, Norway

January 13 2005  

Veenendaal, The Netherlands – Det Norske Radiumhospitalet (DNR) of Norway, one of Europe’s largest radiotherapy centers, has decided to intensify its partnership with Nucletron through expanding the suite of Oncentra oncology software solutions for use throughout the whole hospital.


It is important for DNR to have a flexible software solution in order to integrate their current equipment, and to leverage an industry standard system capable of integrating future systems. Oncentra is the appropriate solution due to its modularity and openness.


With an increase of 3000 new patients in 2003, DNR is now treating approximately 5200 patients per year. With this rapid expansion, it becomes essential to move towards an automated environment and promote system integration that will improve patient care.


“We want to have the freedom to purchase the best equipment available on the market and still have an integrated environment. Therefore the choice is to partner with Nucletron and use Oncentra as the software solution for DNR” states Tor Green, Manager Medical Engineering of DNR.


The cooperation involves expanding the existing Oncentra Information System (OIM), Oncentra Treatment Planning (OTP) and Oncentra Record and Verify (VISIR) systems supplied by Nucletron. The agreement also includes the upgrade of the existing Nucletron simulator into flat panel technology. Furthermore, Nucletron will also deliver a dedicated OTP system with 25 clients for education purposes at the hospital.


DNR was founded in 1932 and has been a long time user of the Oncentra suite with Helax TMS/OTP, VISIR and OIM. They were one of the hospitals originally involved in the development of VISIR as the first accelerator-independent verification system. In addition, since the early nineties DNR has been using Helax TMS, the treatment planning system of Oncentra before OTP.



About Nucletron B.V.

Nucletron is a global leader in the development, manufacture, sales, service and support of the world’s most innovative products for cancer treatment, with particular expertise in treatment planning systems, brachytherapy, simulation, integrated software solutions for oncology, and comprehensive support and professional education and services. The company has over 20 offices worldwide, including its corporate headquarters in Veenendaal, the Netherlands. For more information on Nucletron, please visit: www.nucletron.com.


Nucletron B.V. is a subsidiary of Delft Instruments N.V. Delft Instruments is the holding company of an international group of companies, which hold a leading position in their respective markets with high quality, high technology products and services.  Delft Instruments employs some 1,200 people and reported net profit of EUR 10.4 million on turnover of EUR 237 million in 2003. For more information on Delft Instruments, please visit: http://www.delftinstruments.com/



For further information: